Navigation Links
Neurocrine Biosciences Reports First Quarter 2008 Results
Date:4/30/2008

mpact of 252 Fully Q3 08

period with elagolix elagolix on bone enrolled

and DMPA active mineral density

comparator plus using DXA scan

additional long-term 2. Dysmenorrhea and

safety assessments pelvic pain

post treatment

0702 Placebo-controlled Dysmenorrhea and 150 Enrolling 1H 09

trial with 2 doses pelvic pain

of optimized assessed with

formulation tablet modified endpoints

0703 Placebo-controlled Dysmenorrhea and 180 Initiated 1H 09

trial with 2 doses pelvic pain

of elagolix and assessed with

leuprolide depot modified endpoints

comparator

The Company completed enrollment in December 2007 of a Phase IIb study in which patients with endometriosis will be treated over a 6-month period. This multi-center, randomized, double-blind, study includes three treatment groups, with two doses of elagolix, 150 mg once a day and 75 mg twice daily, and an active comparator, Depo-Provera(R). In addition to confirming the effect of elagolix on endometriosis symptoms, this study is designed primarily to assess the impact of longer term treatment on bone mineral density as measured by DXA scan at the conclusion of dosing and at 6-months and 12-months post-treatment. Topline results from the 6-month treatment period are expected in the third quarter of 2008. The study will continue after the treatment period for DXA scans and safety assessments. The 6-month results, together with data from the other Phase II studies, will be the basis for securing agreement on a registration plan with the FDA.

The Company is also currently conducting two additional randomized placebo controlled Phase II clinical trials. The clinical endpoints for both of these trials are a reduction in pelvic pain associated wit
'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Neurocrine Biosciences Reports Fourth Quarter and Year-End 2007 Results
2. Ardea Biosciences Presents Data Demonstrating Favorable Pharmacokinetics and Efficacy for Mitogen-Activated ERK Kinase (MEK) Inhibitors
3. Sangamo BioSciences Announces Presentation of Data on ZFP Therapeutic for Glioblastoma at American Association for Cancer Research (AACR) Meeting
4. Monogram Biosciences Provides Progenics Pharmaceuticals with HIV Assays for Use in Clinical Trials
5. Sangamo BioSciences and Sigma-Aldrich Announce Publication of Study Demonstrating Zinc Finger Technology for Rapid Generation of Knock-Out Cell Lines
6. Novel PCT Method Unveiled by Pressure BioSciences, Inc. and Collaborators at the Harvard School of Public Health
7. Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load
8. Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus
9. Sangamo BioSciences Reports 2007 Fourth Quarter and Year-End Financial Results
10. CeloNova BioSciences Introduces a New Class of Coronary Stent: The CATANIA(TM) Coronary Stent System with NanoThin Polyzene(R)-F
11. CeloNova BioSciences Announces Positive Results from European Study of Embozene(TM) Microspheres for Treatment of Uterine Fibroids
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... Sept. 17, 2014  The law firm McElroy, ... that it will serve as host for "Show ... the Risks of Healthcare Reform," a one-day conference ... delivery systems, reimbursement, compliance and enforcement in a ... Logo -  http://photos.prnewswire.com/prnh/20140916/146606 Logo -  ...
(Date:9/17/2014)... and LEIPZIG, Germany ... announced that it has entered into an exclusive ... development of antibody-based imaging agents to image CD4+ ... collaboration with Novotectid expands ImaginAb,s capability to precisely diagnose ... and autoimmune disease areas. The ability to image ...
(Date:9/17/2014)... LAWRENCEVILLE, N.J. , Sept. 17, 2014 /PRNewswire-USNewswire/ ... that details how to implement GS1 Standards to ... (DSCSA), and enhance patient safety and security in ... Applying GS1 Standards to U.S. Pharmaceutical Supply ... Chain Security Act , was developed in ...
Breaking Medicine Technology:Three Leading Healthcare Organizations Sponsor Conference to Examine Opportunities and Risks of Healthcare Reform for Providers 2ImaginAb Expands ImmunoPET Pipeline to Include CD4+ T-Cell Imaging 2New Healthcare Industry Guideline Delineates How to Implement GS1 Standards to Support Requirements of the 2013 Drug Supply Chain Security Act 2New Healthcare Industry Guideline Delineates How to Implement GS1 Standards to Support Requirements of the 2013 Drug Supply Chain Security Act 3New Healthcare Industry Guideline Delineates How to Implement GS1 Standards to Support Requirements of the 2013 Drug Supply Chain Security Act 4
(Date:9/17/2014)... Rochelle, NY, September 17, 2014Diffusion Tensor Imaging (DTI), ... detects microstructural changes in brain tissue, can help ... outcomes following mild traumatic brain injury compared to ... according to a new study published in ... Mary Ann Liebert, Inc., publishers . The ...
(Date:9/17/2014)... CORVALLIS, Ore. People with facial paralysis are perceived ... in the universal language of facial expression, a new ... , The findings highlight the important role the ... hold a prejudice against those with facial paralysis because ... of psychology in the College of Liberal Arts at ...
(Date:9/17/2014)... (PRWEB) September 17, 2014 Fasoo ... Security Testing (SAST) tool, at AppSec USA 2014 in ... 9 am to 6 pm at booth G4 inside ... of the leading software security conferences for developers, auditors, ... tool that provides developers and managers with the ability ...
(Date:9/17/2014)... Elsevier, a world-leading provider of scientific, technical and ... publication of a position statement by the European ... Maturitas on the topic of breast ... prevalent cancer in women, with slightly more than ... Mammography screening is a well-established method to detect ...
(Date:9/17/2014)... September 17, 2014 In ongoing ... Inc.’s Drug Benefit News (DBN) continues to find ... in its Aug. 8 issue , CVS Caremark ... lists for 2015 each cut more drugs than ... savings these exclusions are likely to achieve. Despite ...
Breaking Medicine News(10 mins):Health News:New MRI technique helps clinicians better predict outcomes following mild traumatic brain injury 2Health News:Lack of facial expression leads to perceptions of unhappiness, new OSU research shows 2Health News:Lack of facial expression leads to perceptions of unhappiness, new OSU research shows 3Health News:Fasoo to Introduce Their Testing Tool to Improve Software Security and Quality at AppSec USA 2014 2Health News:AIS Newsletter Continues to Find Industry Criticism of PBM Formulary Exclusion Lists 2Health News:AIS Newsletter Continues to Find Industry Criticism of PBM Formulary Exclusion Lists 3
... Netherlands / Rockville, MD, USA (September 22, 2010) ... Exchange: CRX) and the Aeras Global TB Vaccine Foundation ... trial in infants of the jointly developed tuberculosis (TB) ... of the trial is to test the safety and ...
... of Cincinnati (UC) researcher will receive $2.5 million over ... (NIDA) to support his work on a potential immunotherapy ... in the psychiatry and behavioral neuroscience department, is one ... Awards for Innovative Medication Development Research. Award winners receive ...
... HealthDay Reporter , TUESDAY, Sept. 21 (HealthDay ... suicide rates appear to be highest among residents of ... fresh research points to a possible explanation: high altitudes. ... and the high prevalence of gun ownership, may contribute ...
... therapies against cancer to be effective, scientists need to ... makes a cancer cell resistant to a drug and ... Lombardi Comprehensive Cancer Center and Fox Chase Cancer Center. ... , the investigators discuss how cancer cells activate a ...
... of Rhode Island Hospital, is the recipient of the ... Imaging Network (ACRIN). Dupuy received the award for leading ... (RFA) to reduce the pain of osseous metastases (cancer ... scientific paper published during the previous year that stands ...
... Physicians now have access to real time radiology ... Viewbox (patent pending) is a portable interface system ... specialist consultation to physicians using any internet-ready device. ... in transmitting patient information and offers a timely ...
Cached Medicine News:Health News:Aeras and Crucell announce Phase II clinical trial start in Kenya 2Health News:Aeras and Crucell announce Phase II clinical trial start in Kenya 3Health News:Aeras and Crucell announce Phase II clinical trial start in Kenya 4Health News:Researcher wins $2.5 million award from National Institute on Drug Abuse 2Health News:Is High Altitude Linked to Suicide Risk? 2Health News:Is High Altitude Linked to Suicide Risk? 3Health News:Targeted therapy triggers complex mechanism of resistance 2Health News:Targeted therapy triggers complex mechanism of resistance 3Health News:Targeted therapy triggers complex mechanism of resistance 4Health News:Rhode Island Hospital physician receives national award for research 2Health News:Virtual Viewbox offers portable radiology access for physicians 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: